$452M vs the Public: How Pharma Kills Drug Pricing Reform

The $452 Million Wall

No industry in America spends more on lobbying than pharmaceuticals. The sector's $452 million in 2024 federal lobbying — led by the trade group PhRMA and individual companies like Pfizer, Johnson & Johnson, and AbbVie — represents the highest lobbying total of any industry in any year in American history.

The American Drug Price Crisis

Americans pay dramatically more for prescription drugs than citizens of any other developed country:

• Insulin: Average U.S. price $98.70/vial vs. $8-12 in Canada, UK, Germany
• Humira (arthritis): U.S. list price $6,922/month vs. $1,362 in the UK
• Keytruda (cancer): U.S. price $189,000/year vs. $91,000 in the UK
• Ozempic (diabetes/weight loss): U.S. price $935/month vs. $59-155 in most other countries
• Overall: Americans pay on average 2.56 times more than citizens of other OECD countries for the same drugs

The reason is simple: the United States is the only developed country that does not regulate drug prices at the national level. Other countries negotiate prices through government health systems. In the U.S., drug companies charge whatever the market will bear.

The Inflation Reduction Act: A Small Victory

The 2022 Inflation Reduction Act (IRA) represented the first-ever authorization for Medicare to negotiate drug prices directly with manufacturers. But the law was dramatically weakened by pharma lobbying before passage:

• Only 10 drugs could be negotiated in the first year (2026), rising to 20 by 2029
• New drugs were excluded for 9-13 years after FDA approval — protecting the most expensive launch prices
• Small molecule drugs (pills) could be negotiated after 9 years; biologics (injections) after 13 years — incentivizing companies to develop biologics, which are harder to make generically
• No negotiation for private insurance — only Medicare Part D

Even this modest reform was too much for the industry. PhRMA and individual drug companies filed nine federal lawsuits challenging the IRA's negotiation provisions, arguing that forcing companies to accept lower prices amounted to unconstitutional "coercion."

The Lobbying Kill List

The pharmaceutical industry has killed or gutted every major drug pricing reform proposed in the last 25 years:

• 2003: Medicare Part D created without price negotiation authority — pharma wrote the bill
• 2009: Obama cut a deal with PhRMA to limit ACA drug pricing provisions to $80B in savings over 10 years
• 2019: Pelosi's Lower Drug Costs Now Act — passed House, blocked in Senate
• 2019: Trump's drug importation executive order — never implemented after pharma lobbying
• 2021: Build Back Better drug pricing provisions — weakened repeatedly, final version in IRA covers only 10-20 drugs
• 2025: IRA expansion proposals — dead on arrival in Republican Congress

The Campaign Contribution Pipeline

Pharma's lobbying is complemented by massive campaign contributions:

• $86 million in PAC and individual contributions in the 2024 cycle
• $35 million to Republican candidates and committees
• $29 million to Democratic candidates and committees
• $22 million in outside spending through industry-funded groups

The industry gives to both parties because it needs allies on both sides. Democrats control the votes; Republicans provide the opposition. The industry maintains relationships with all of them.

The Global Comparison

Sources

• OpenSecrets: Pharmaceutical/health products lobbying data
• RAND Corporation: "International Prescription Drug Price Comparisons" (2024)
• Commonwealth Fund: Cross-national drug price analysis
• CMS: Medicare Part D spending data
• PhRMA: Annual lobbying disclosures
• Federal court dockets: IRA legal challenges
• Congressional Budget Office: IRA savings estimates